1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The POLARIX study: Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma
    Meeting Abstract

    Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; Rai, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: Final data
    Journal Article

    Horwitz, S. M.; Scarisbrick, J. J.; Dummer, R.; Whittaker, S.; Duvic, M.; Kim, Y. H.; Quaglino, P.; Zinzani, P. L.; Bechter, O.; Eradat, H.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Real-world assessment of patient care and practice efficiency with the introduction of subcutaneous rituximab
    Journal Article

    Drill, E.; Qiu, A.; Shapouri, S.; Tu My, T.; Ravelo, A.; Schade, J.; Dawson, K.; Matasar, M.
    Oncology (Norwalk) (2021)

    Fulltext@MSK | Save
  • How to choose first salvage therapy in Hodgkin lymphoma: Traditional chemotherapy vs novel agents
    Review

    Driessen, J.; Tonino, S. H.; Moskowitz, A. J.; Kersten, M. J.
    Hematology-American Society of Hematology Education Program (2021)

    Fulltext@MSK | Save
  • IVAC with or without rituximab for relapsed or refractory B-cell non-Hodgkin lymphomas: Real-world experience in the modern era
    Journal Article

    Buege, M. J.; Dao, P. H.; Drill, E.; LeVoir, A.; Pak, T.; Peterson, T. J.; Straus, D. J.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial
    Journal Article

    Horwitz, S.; Zinzani, P. L.; Bagot, M.; Kim, Y. H.; Moskowitz, A. J.; Porcu, P.; Dwyer, K.; Sun, W.; Herr, F. M.; Scarisbrick, J.
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Challenges and opportunities in 2021
    Editorial

    Akkari, L.; Finley, S. D.; Ho, P. C.; Jenkins, M.; Maier, B. B.; McGranahan, N.; Mutebi, M.; Perera, R. M.; Robles-Espinoza, C. D.; Vardhana, S.; more...
    Nature Cancer (2021)

    Fulltext@MSK | Save
  • Diffuse large B-cell lymphoma: Optimizing therapy for relapsed/refractory disease
    Editorial

    Matasar, M. J.
    Journal of the National Comprehensive Cancer Network (2021)

    Fulltext@MSK | Save
  • NCCN Guidelines® Insights: B-cell lymphomas, version 5.2021: Featured updates to the NCCN Guidelines
    Guidelines

    Zelenetz, A. D.; Gordon, L. I.; Chang, J. E.; Christian, B.; Abramson, J. S.; Advani, R. H.; Bartlett, N. L.; Budde, L. E.; Caimi, P. F.; De Vos, S.; more...
    Journal of the National Comprehensive Cancer Network (2021)

    Fulltext@MSK | Save